Identification of early predictive imaging biomarkers and their relationship to serological angiogenic markers in patients with ovarian cancer with residual disease following cytotoxic therapy.
BACKGROUND
Patients with recurrent ovarian cancer often achieve partial response following chemotherapy, resulting in persistent small volume disease. After completion of treatment, the dilemma of when to initiate subsequent chemotherapy arises. Identification of biomarkers that could be used to predict when subsequent treatment is needed would be of significant benefit.


METHODS
Twenty-three patients with advanced ovarian cancer and residual asymptomatic disease following chemotherapy underwent dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) at study entry, 4, 8, 12, 18 and 26 weeks or disease progression. A subgroup of patients provided plasma samples within which a panel of angiogenic biomarkers was quantified.


RESULTS
By 4 weeks, significant differences in whole tumour volume, enhancing fraction and Ca125 were observed between patients whose disease progressed by 26 weeks and those who remained stable. Significant correlations between plasma soluble vascular endothelial growth factor receptor-1 (sVEGFR-1) and sVEGFR-2 concentrations, and blood volume and tumour endothelial permeability surface area product measured by DCE-MRI were observed.


CONCLUSIONS
Imaging markers have a potential role in early prediction of disease progression in patients with residual ovarian cancer and may supplement current measures of progression. The correlation of DCE-MRI and serological biomarkers suggests that tumour angiogenesis affects these markers through common biological means and warrants further investigation.
Mitchell
C L
CL
Cancer Research UK, Department of Medical Oncology, Christie Hospital and University of Manchester. Electronic address: cmitchell@picr.man.ac.uk.
O'Connor
J P B
JPB
Cancer Research UK, Department of Medical Oncology, Christie Hospital and University of Manchester; Imaging Science and Biomedical Engineering Department, School of Cancer and Imaging Sciences, University of Manchester.
Jackson
A
A
Imaging Science and Biomedical Engineering Department, School of Cancer and Imaging Sciences, University of Manchester.
Parker
G J M
GJM
Imaging Science and Biomedical Engineering Department, School of Cancer and Imaging Sciences, University of Manchester.
Roberts
C
C
Imaging Science and Biomedical Engineering Department, School of Cancer and Imaging Sciences, University of Manchester.
Watson
Y
Y
Imaging Science and Biomedical Engineering Department, School of Cancer and Imaging Sciences, University of Manchester.
Cheung
S
S
Imaging Science and Biomedical Engineering Department, School of Cancer and Imaging Sciences, University of Manchester.
Davies
K
K
Imaging Science and Biomedical Engineering Department, School of Cancer and Imaging Sciences, University of Manchester.
Buonaccorsi
G A
GA
Imaging Science and Biomedical Engineering Department, School of Cancer and Imaging Sciences, University of Manchester.
Clamp
A R
AR
Cancer Research UK, Department of Medical Oncology, Christie Hospital and University of Manchester.
Hasan
J
J
Cancer Research UK, Department of Medical Oncology, Christie Hospital and University of Manchester.
Byrd
L
L
Cancer Research UK, Department of Medical Oncology, Christie Hospital and University of Manchester.
Backen
A
A
Department of Clinical and Experimental Pharmacology, Paterson Institute for Cancer Research, University of Manchester, Manchester, UK.
Dive
C
C
Department of Clinical and Experimental Pharmacology, Paterson Institute for Cancer Research, University of Manchester, Manchester, UK.
Jayson
G C
GC
Cancer Research UK, Department of Medical Oncology, Christie Hospital and University of Manchester; Department of Clinical and Experimental Pharmacology, Paterson Institute for Cancer Research, University of Manchester, Manchester, UK.
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000097:blood*; D018394:CA-125 Antigen / Q000097:blood; D003287:Contrast Media; D018284:Cystadenocarcinoma, Serous / Q000097:blood / Q000175:diagnosis* / Q000188:drug therapy; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D008279:Magnetic Resonance Imaging; D008565:Membrane Proteins / Q000097:blood; D009364:Neoplasm Recurrence, Local / Q000097:blood / Q000175:diagnosis* / Q000188:drug therapy; D009367:Neoplasm Staging; D018365:Neoplasm, Residual / Q000097:blood / Q000175:diagnosis* / Q000188:drug therapy; D009389:Neovascularization, Pathologic; D010051:Ovarian Neoplasms / Q000097:blood / Q000175:diagnosis* / Q000188:drug therapy; D010534:Peritoneal Neoplasms / Q000097:blood / Q000175:diagnosis* / Q000188:drug therapy; D011379:Prognosis; D015996:Survival Rate; D040281:Vascular Endothelial Growth Factor Receptor-1 / Q000097:blood; D040301:Vascular Endothelial Growth Factor Receptor-2 / Q000097:blood
D014408:Biomarkers, Tumor; D018394:CA-125 Antigen; D003287:Contrast Media; C451759:MUC16 protein, human; D008565:Membrane Proteins; D040281:Vascular Endothelial Growth Factor Receptor-1; D040301:Vascular Endothelial Growth Factor Receptor-2